Regorafenib for Recurrent Meningioma (MIRAGE Trial)
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
What the trial team says
The focus of this study will be to investigate whether Regorafenib demonstrates antitumor activity against recurrent meningiomas. Small trials and case series suggest clinical relevant activity of several VEGF inhibitors such as sunitinib, bevacizumab and valatinib reporting a 6m-PFS rate of 42-64%. Indeed, VEGF and VEGF receptors (VEGFR) are regularly overexpressed in meningiomas and can correlate with outcome. Regorafenib inhibits angiogenic receptor tyrosine kinases (RTKs) and is highly selective for VEGFR1/2/3; moreover Regorafenib inhibits PDGFRB, FGFR1 and oncogenic intracellular signalling cascades involving c-RAF/RAF1 and BRAF highly expressed in meningiomas. Noteworthy, Regorafenib showed antitumor activity in vitro and in vivo in a recent study; indeed, Regorafenib showed significant inhibition of meningioma cell motility and invasion and in vivo, mice with orthotopic meningioma xenografts showed a reduced volume of signal enhancement in MRI following Regorafenib therapy; this translated in a significantly increased overall survival time (p\<0.05) for Regorafenib treated mice. Moreover, Regorafenib showed good efficacy in different cancer types, such as colorectal cancer, GIST, hepatocellular carcinoma and glioblastoma (REGOMA trial) , maintainingmaintaining a good quality of life.
Key facts
- Registry number
- NCT06275919
- Stage of testing
- Phase 2
- Conditions studied
- Meningioma, Malignant
Where it is running
This trial lists 20 sites.
-
Forlì-Cesena
- IRST Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (Meldola)
-
Italia/Messina
- Azienda Ospedaliera Universitaria Gaetano Martino (Messina)
-
Italy
- A.O.U. Policlinico di Bari (Bari)
- Ospedale San Paolo (Bari)
- Ospedale Bellaria - AUSL Bologna (Bologna)
- Azienda Ospedaliero Universitaria Careggi (Florence)
- Policlinico San Martino (Genova)
- Spedali Riuniti (Livorno)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (Milan)
- IRCCS Ospedale San Raffaele (Milan)
- Ospedale del Mare (Naples)
- Istituto Oncologico Veneto (Padova)
- Azienda Ospedaliera di Perugia (Perugia)
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Roma)
- and 3 more in Italy
-
Italy, Firenze
- Ospedale Santa Maria Annunziata (Bagno a Ripoli)
-
Italy, PN
- Centro di Riferimento Oncologico di Aviano (CRO), IRCCS (Aviano)
-
Milano
- Humanitas Cancer Center (Rozzano)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.